<DOC>
	<DOCNO>NCT03101670</DOCNO>
	<brief_summary>This multicenter , Phase 2 , double-blind , placebo-controlled study subject moderately severely active Psoriatic Arthritis ( PsA ) inadequate response intolerant conventional disease-modifying therapy . A total approximately 124 subject randomize one 2 treatment arm 1:1 ratio : oral filgotinib tablet q.d . match placebo tablet q.d . The Screening visit occur within 28 day study drug administration . At Day 1 ( Baseline ) , eligible subject randomize treatment duration 16 week . The study conclude Follow-up period last 4 week last dose . Consequently , subject stay study maximum 24 week ( Screening visit Follow-up visit ) .</brief_summary>
	<brief_title>A Study Assess Efficacy Safety Filgotinib Active Psoriatic Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Psoriatic</mesh_term>
	<criteria>Key Male female subject ≥18 year age , day signing inform consent . Diagnosis psoriatic arthritis meeting Classification Criteria Psoriatic Arthritis ( CASPAR ) Have active psoriatic arthritis define ≥5 swollen joint ( 66 swell joint count [ SJC ] ) ≥5 tender joint ( 68 tender joint count [ TJC ] ) Screening Baseline ( measurable dactylitis digit count single swollen joint tender , also single tender joint ) . Have history document plaque psoriasis currently active plaque psoriasis If use cDMARD therapy , subject must 12 week prior screen , stable dose ( include stable route administration ) least 4 week prior baseline . If use nondrug therapy ( include physical therapy ) , thse keep sable screen Male female subject childbearing potential engage heterosexual intercourse must agree use highly effective method contraception describe protocol Key Use JAK inhibitor , investigational approve , time , include filgotinib ; Prior use one TNF inhibitor , time . Use oral steroid dose &gt; 10 mg/day prednisone prednisone equivalent dose n't stable least 4 week prior Baseline ; Any therapy intraarticular injection ( e.g . corticosteroid , hyaluronate ) within 4 week prior screen ; Use 1 NSAID cyclooxygenase2 ( COX2 ) inhibitor . Have undergone surgical treatment psoriatic arthritis include synovectomy arthroplasty 3 joint and/or within last 12 week prior screen Presence poor functional status unable perform selfcare . Administration live attenuate vaccine within 12 week prior baseline</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>